Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
Roy M FleischmannEduardo MyslerLouis BessetteCharles G PeterfyPatrick DurezYoshiya TanakaJerzy SwierkotNasser KhanXianwei BuYihan LiIn-Ho SongPublished in: RMD open (2022)
The safety profile of UPA 15 mg was consistent with previous study-specific and integrated safety reports. Higher levels of clinical response continued to be observed with upadacitinib versus adalimumab through 3 years of treatment.